Vor Biopharma (VOR) Depreciation & Amortization (CF) (2025)

Vor Biopharma (VOR) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $28000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 96.5% year-over-year to $28000.0; the TTM figure through Mar 2026 stood at $2.2 million (down 36.29% YoY), while the FY2025 annual figure was $2.9 million, down 17.14% from the prior year.
• Depreciation & Amortization (CF) declined to $28000.0 in Q1 2026 per VOR's latest filing, from $36000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q2 2025 and bottomed at $2000.0 in Q3 2025.
• Historically, Depreciation & Amortization (CF) has averaged $739000.0 across 5 years, with a median of $837000.0 in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 200.0% — and 2025, when it sank 99.78%.
• Vor Biopharma's Depreciation & Amortization (CF) stood at $625000.0 in 2022, then jumped by 42.72% to $892000.0 in 2023, then slipped by 10.31% to $800000.0 in 2024, then plunged by 95.5% to $36000.0 in 2025, then decreased by 22.22% to $28000.0 in 2026.
• Business Quant data shows VOR's Depreciation & Amortization (CF) at $28000.0 in Q1 2026, $36000.0 in Q4 2025, and $2000.0 in Q3 2025.